
DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
One Pill Makes You Better?
over 16 years ago
Weathering the Compliance Stormover 16 years ago
Pharma's Orphansover 16 years ago
Tech Toys 2: Revenge of the Appover 16 years ago
Five Policies for Pharma's Big 50over 16 years ago
Healthcare Hung Up in the UK Election?over 16 years ago
How to Become a Commitment Catalyst?over 16 years ago
Pharma's Big Tradeoff





